Rezolute KOL Event Highlights Significant Unmet Medical
RZ402 is an oral therapy being developed as a potential alternative to anti-vascular growth factor (anti-VEGF) injections into the eye...
Stay updated with breaking news from Robert Bhisitkul. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
RZ402 is an oral therapy being developed as a potential alternative to anti-vascular growth factor (anti-VEGF) injections into the eye...
REDWOOD CITY, Calif., March 23, 2023 -- Rezolute, Inc. , a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to shift the treatment... | March 23, 2023
RZ402 is an oral therapy being developed as a potential alternative to anti-vascular growth factor (anti-VEGF) injections into the eyeREDWOOD CITY, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceuti...
Investor call with retinal expert Robert Bhisitkul, M.D., Ph.D., to be held on Friday, August 12 at 5:00 a.m. PT/8:00 a.m. ...